MedTrace Logo

A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

NCT05409027 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-04-22

No results posted yet for this study

Summary

This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)

Conditions

  • Type 2 Diabetes Mellitus in Obese
  • Obesity
  • Type2Diabetes

Interventions

DRUG

SPI-62

SPI-62 is supplied as 1 mg tablets for oral dosing.

DRUG

Cortisone-d8

Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion

Sponsors & Collaborators

  • Sparrow Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • David Katz, PhD · Sparrow Pharmaceuticals

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-23
Primary Completion
2022-03-10
Completion
2024-02-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05409027 on ClinicalTrials.gov